Abstract: A terminal apparatus for which a master cell group and a secondary cell group are configured includes an RRC entity. The RRC entity receives a first reporting from a lower layer entity, and generates a message for requesting activation of the secondary cell group, based on the first reporting.

Abstract: The purpose of the present invention is to provide a novel stereoselective method for preparing a cyclic dinucleotide derivative and a production intermediate therefor, which can be used for an antibody-immunostimulant conjugate. Also provided is a method for producing a cyclic dinucleotide-linker and an antibody-immunostimulant conjugate while using the above production method. Further provided is a method for preparing a cyclic dinucleotide derivative, the method including the step of subjecting a compound (I) and a compound (IV) to stereoselective condensation using an optically active phosphitylating agent (Rc-II) or (Sc-II).

Abstract: A terminal apparatus for communicating with a first terminal apparatus and a second terminal apparatus is responsible to relay communication between the first terminal apparatus and the second terminal apparatus. The terminal apparatus measures a sidelink Reference Signal Received Power (SL-RSRP) in each of communication with the first terminal apparatus and communication with the second terminal apparatus, and determines whether the two SL-RSRPs are equal to or greater than a threshold and notifies the first terminal apparatus that the first terminal apparatus and the second terminal apparatus are in proximity in a case that the two SL-RSRPs are determined to be equal to or greater than the threshold, and does not notify the first terminal apparatus that the first terminal apparatus and the second terminal apparatus are in proximity in a case that the two SL-RSRPs are not determined to be equal to or greater than the threshold.

Abstract: A terminal apparatus for communicating with a second terminal apparatus via a first terminal apparatus is responsible to relay communication between the first terminal apparatus and the second terminal apparatus. The terminal apparatus receives a sidelink transmission including first Sidelink Control Information (SCI) and a sidelink transmission including second SCI corresponding to the first SCI, measures a Sidelink Reference Signal Received Power (SL-RSRP) from the sidelink transmission including the first SCI, and associates the measured SL-RSRP with an identifier included in the second SCI, and notifies a higher layer of the measured SL-RSRP and the identifier, the identifier indicating a transmission source of the sidelink transmission including the first SCI.

Abstract: A terminal apparatus for communicating with a second terminal apparatus via a first terminal apparatus. The third terminal apparatus receives a sidelink transmission from the second terminal apparatus to the first terminal apparatus, measures a sidelink Reference Signal Received Power (SL-RSRP) from the received sidelink transmission, and determines whether the SL-RSRP is equal to or greater than a threshold, and notifies a higher layer that the second terminal apparatus is in proximity in a case that the SL-RSRP is determined to be equal to or greater than the threshold, and does not notify the higher layer that the second terminal apparatus is in proximity in a case that the SL-RSRP is not determined to be equal to or greater than the threshold.

Abstract: A terminal apparatus for communicating with a first terminal apparatus and a second terminal apparatus is responsible to relay communication between the first terminal apparatus and the second terminal apparatus, and transmits, to the second terminal apparatus, a configuration for sidelink reception used for communication with the first terminal apparatus.

Abstract: A terminal apparatus for communicating with a first terminal apparatus and a second terminal apparatus is responsible to relay communication between the first terminal apparatus and the second terminal apparatus, and includes a processing unit and a transmitter, and the processing unit transmits a sidelink reception configuration for the first terminal apparatus to the second terminal apparatus.

Abstract: A cutting machining apparatus includes: a holding unit including a workpiece holder, a tool holder, and a unit body; a head positioned facing the holding unit and including a chuck holding a tool; an interior case of a box shape including, in a peripheral wall, a first opening through which the holding unit is inserted and a second opening through which the head is inserted and housing the workpiece holder, the tool holder, and the chuck disposed inside; a first cover occluding between the head and the outer periphery of the first opening of the interior case, a second cover occluding between the holding unit and the outer periphery of the second opening of the interior case, and a cooling source cooling the tool holder from within the unit body via a heat transfer member.

Abstract: A terminal apparatus for communicating with a base station apparatus by using a direct path and an indirect path determines whether a signaling radio bearer is configured on an indirect path in a case that radio link failure is detected on the direct path, and transmits information indicating that the radio link failure has occurred on the direct path via the signaling radio bearer in a case that the signaling radio bearer is determined to be configured on the indirect path.

Abstract: A terminal apparatus for communicating with a base station apparatus by using a direct path and an indirect path determines whether a signaling radio bearer is configured on the indirect path in a case that radio link failure is detected on the direct path and the signaling radio bearer is not configured with a split bearer, and a transmitter transmits information indicating that the radio link failure has occurred on the direct path via a sidelink signaling radio bearer configured between the terminal apparatus and the relay terminal apparatus in a case that the signaling radio bearer is determined to not be configured on the indirect path.

Abstract: A terminal apparatus for communicating with a base station apparatus by using a direct path and an indirect path determines whether a signaling radio bearer is configured on the direct path in a case that radio link failure is detected on the indirect path and a signaling radio bearer is not configured with a split bearer, and transmits, via the signaling radio bearer, information indicating that the radio link failure has occurred on the indirect path in a case that the signaling radio bearer is determined to be configured on the direct path.

Abstract: A vehicle windshield wiper blade comprising: a blade support portion; and a lip portion, wherein the lip portion has a tapered portion having a cross section that is taken along a direction perpendicular to the longitudinal direction of the wiper blade and that has a width that gradually decreases from a side closer to the blade support portion towards a direction farthest away from the blade support portion, the lip portion has a tip surface and first and second tapered surfaces constituting the tapered portion, and, in a specific observation region of the first and second tapered surfaces, the average value of the elastic modulus measured at a 0.1 ?m pitch is 15-470 MPa and the coefficient of variation of the elastic modulus is at most 17.6%.

Abstract: The present invention provides a novel compound or a pharmaceutically acceptable salt thereof having an inhibitory action on an EGFR tyrosine kinase having an exon 20 insertion mutation and/or a HER2 tyrosine kinase having an exon 20 insertion mutation, a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, R4, R5 and R6 in the Formula (I) are each as defined in the description.

Abstract: Cystic fibrosis is developed through mutation of Cystic Fibrosis Transmembrane conductance Regulator (CFTR), which is one type of chloride channel. An object of the present invention is to provide compounds effective in the treatment of cystic fibrosis that open a chloride channel different from CFTR, which is the cause of the disease, and do not depend on CFTR. Compounds of the present invention are compounds or pharmaceutically acceptable salts thereof that open calcium dependent chloride channels (CaCCs) via G-protein coupled receptor 39 (GPR39) agonism to have strong chloride ion-secretory action, and are represented by the following general formula (I): General formula (I): wherein, X represents a carboxyl group or a tetrazolyl group; Q represents a C1-C3 alkylene group, an oxygen atom, a sulfur atom, etc.; G represents a phenyl group where the phenyl group may have 1 to 3 substituents independently selected from the group consisting of a halogen atom, a cyano group, a C1-C6 alkyl group, etc.

Abstract: Provided is a novel compound or a salt thereof inhibiting MTHFD2 and useful for treating a disease caused by overexpression of MTHFD2, a disease involved in overexpression of MTHFD2 and/or a disease associated with overexpression of MTHFD2. Solution Provided is a sulfonamide derivative having a coumarin skeleton represented by the following formula (I) and having various substituents: wherein R1, R2, R3, R4, R5, R6 and R7 are the same as defined in the specification, and a salt thereof.

Abstract: Cystic fibrosis is developed through mutation of Cystic Fibrosis Transmembrane conductance Regulator (CFTR), which is one type of chloride channel. An object of the present invention is to provide compounds effective in the treatment of cystic fibrosis that open a chloride channel different from CFTR, which is the cause of the disease, and do not depend on CFTR. Compounds of the present invention are compounds or pharmaceutically acceptable salts thereof that open calcium dependent chloride channels (CaCCs) via G-protein coupled receptor 39 (GPR39) agonism to have strong chloride ion-secretory action, and are represented by the following general formula (I): General formula (I): wherein, X represents a carboxyl group or a tetrazolyl group; Q represents a C1-C3 alkylene group, an oxygen atom, a sulfur atom, etc.; G represents a phenyl group where the phenyl group may have 1 to 3 substituents independently selected from the group consisting of a halogen atom, a cyano group, a C1-C6 alkyl group, etc.

Abstract: Provided is a novel compound or a salt thereof inhibiting MTHFD2 and useful for treating a disease caused by overexpression of MTHFD2, a disease involved in overexpression of MTHFD2 and/or a disease associated with overexpression of MTHFD2. Solution Provided is a sulfonamide derivative having a coumarin skeleton represented by the following formula (I) and having various substituents: wherein R1, R2, R3, R4, R5, R6 and R7 are the same as defined in the specification, and a salt thereof.

Abstract: Compounds having PDE10A inhibitory activity and having general formula (I), or an isotope thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient.

Abstract: [Problem to be Solved] It is intended to provide a compound having PDE10A inhibitory activity and having a novel structure, or an isotope thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient. [Solution] The present invention provides a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: To provide thienopyrazole derivatives inhibiting PDE 7 selectively, and therefore, enhance cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic diseases, inflammatory diseases or immunologic diseases. The compound is thienopyrazole compound represented by the following formula (I): [wherein, especially, R1 is a cyclohexyl, a cycloheptyl group or a tetrahydropyranyl group; R2 is methyl; R3 is a hydrogen atom; and R4 is a group: —CONR5R6 (in which any one of R5 and R6 is a hydrogen atom)].